An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...

Gilead Sciences (NASDAQ ... Overview of Peer Analysis The peer analysis summary presents essential metrics for Vertex Pharmaceuticals, Regeneron Pharmaceuticals and Amgen, unveiling their ...

A Pennsylvania federal district court denied summary judgment to Gilead Sciences, Inc. on the wrongful discharge claim under state law of an employed at-will therapeutic specialist who sold its ...

Scottish Medicines Consortium Accepts Kite CAR T-Cell Therapy for Earlier Use to Treat Aggressive Blood Cancers - First SMC acceptance of any CAR T-cell therapy for lymphoma patients in the ...

Gilead Sciences, Inc. (NASDAQ ... and median overall survival was not yet reached. In summary, we are encouraged by the compelling results so far, and with over 140 patients dosed across both the ...

Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with ...

Global Regenerative Medicine Market is valued at approximately USD 34.56 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 32.4% over the forecast period 2024-2032.

Support OpenSecrets during our NewsMatch campaign and double your donation! Help keep our resources and data free for the general public.